In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.

Inclusion Criteria:

1. patients who underwent liver resection
2. patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC

Exclusion Criteria:

1. patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
2. patients diagnosed with other specific types of sarcomas;
3. patients with concurrent other malignancies during the course of PHSC;
4. patients who were lost to follow-up or lacked essential clinical data.

The data was collected from patients who underwent liver resection and were diagnosed with PHSC pathologically. The data was collected from the division of Liver Surgery of West China Hospital, SCU from December 2018 to May 2023.